King Pharma's Second Quarter Disappoints; Looks to Pain Approvals and Diversification

With the Skelaxin story "over," King is pushing ahead with plans to resubmit abuse-deterrent opioids Remoxy and Acurox for FDA approval and fine-tuning its sales force to improve performance of Embeda.